Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 37,446 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on March 22, 2006, and the Company was advised of it on March 23, 2006.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same capacity as other employees. No guidance, outlook, or specific risk factors are discussed in this text.
Key Facts for Investor Verification
- Transaction Date: March 22, 2006.
- Shares Transferred: 37,446 Ordinary Shares.
- Source: GlaxoSmithKline Employee Trust (Abacus (GSK) Trustees Limited).
- Destination: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Regulatory Basis: Notification in accordance with Disclosure Rule 3.1.4 R(1)(b).